Sex differences in adverse reactions to antiretroviral drugs.

Ighovwerha Ofotokun, Claire Pomeroy

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

There have been recent increases in the number of female participants in HIV clinical trials and the number of studies addressing the influence of sex on HIV infection. The findings of some studies indicate a potential sex differences in the frequency and severity of adverse reactions to antiretroviral drugs. This article reviews the available data on the incidence and characteristics of potential sex differences in adverse reactions to certain nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Adverse effects for which a sex difference has been reported include lactic acidosis, rash, elevation in liver enzymes, dyslipidemia, and insulin resistance. The reasons for these sex differences in adverse drug events are unclear but may include differences between men and women in body mass index and fat composition, hormonal effects on drug metabolism, or the effects of genomic constitutional differences on the levels of various enzymes. These differences warrant further study.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalTopics in HIV medicine : a publication of the International AIDS Society, USA
Volume11
Issue number2
StatePublished - 2003
Externally publishedYes

Fingerprint

Sex Characteristics
Pharmaceutical Preparations
Lactic Acidosis
Reverse Transcriptase Inhibitors
Enzymes
Dyslipidemias
Exanthema
Protease Inhibitors
Drug-Related Side Effects and Adverse Reactions
Nucleosides
HIV Infections
Insulin Resistance
Body Mass Index
Fats
Clinical Trials
HIV
Liver
Incidence

Cite this

Sex differences in adverse reactions to antiretroviral drugs. / Ofotokun, Ighovwerha; Pomeroy, Claire.

In: Topics in HIV medicine : a publication of the International AIDS Society, USA, Vol. 11, No. 2, 2003, p. 55-59.

Research output: Contribution to journalArticle

@article{e5c9da8aa2cc4b399f8c5389ab3eeaa0,
title = "Sex differences in adverse reactions to antiretroviral drugs.",
abstract = "There have been recent increases in the number of female participants in HIV clinical trials and the number of studies addressing the influence of sex on HIV infection. The findings of some studies indicate a potential sex differences in the frequency and severity of adverse reactions to antiretroviral drugs. This article reviews the available data on the incidence and characteristics of potential sex differences in adverse reactions to certain nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Adverse effects for which a sex difference has been reported include lactic acidosis, rash, elevation in liver enzymes, dyslipidemia, and insulin resistance. The reasons for these sex differences in adverse drug events are unclear but may include differences between men and women in body mass index and fat composition, hormonal effects on drug metabolism, or the effects of genomic constitutional differences on the levels of various enzymes. These differences warrant further study.",
author = "Ighovwerha Ofotokun and Claire Pomeroy",
year = "2003",
language = "English (US)",
volume = "11",
pages = "55--59",
journal = "Topics in antiviral medicine",
issn = "2161-5861",
publisher = "International Antiviral Society",
number = "2",

}

TY - JOUR

T1 - Sex differences in adverse reactions to antiretroviral drugs.

AU - Ofotokun, Ighovwerha

AU - Pomeroy, Claire

PY - 2003

Y1 - 2003

N2 - There have been recent increases in the number of female participants in HIV clinical trials and the number of studies addressing the influence of sex on HIV infection. The findings of some studies indicate a potential sex differences in the frequency and severity of adverse reactions to antiretroviral drugs. This article reviews the available data on the incidence and characteristics of potential sex differences in adverse reactions to certain nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Adverse effects for which a sex difference has been reported include lactic acidosis, rash, elevation in liver enzymes, dyslipidemia, and insulin resistance. The reasons for these sex differences in adverse drug events are unclear but may include differences between men and women in body mass index and fat composition, hormonal effects on drug metabolism, or the effects of genomic constitutional differences on the levels of various enzymes. These differences warrant further study.

AB - There have been recent increases in the number of female participants in HIV clinical trials and the number of studies addressing the influence of sex on HIV infection. The findings of some studies indicate a potential sex differences in the frequency and severity of adverse reactions to antiretroviral drugs. This article reviews the available data on the incidence and characteristics of potential sex differences in adverse reactions to certain nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors. Adverse effects for which a sex difference has been reported include lactic acidosis, rash, elevation in liver enzymes, dyslipidemia, and insulin resistance. The reasons for these sex differences in adverse drug events are unclear but may include differences between men and women in body mass index and fat composition, hormonal effects on drug metabolism, or the effects of genomic constitutional differences on the levels of various enzymes. These differences warrant further study.

UR - http://www.scopus.com/inward/record.url?scp=0037647146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037647146&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 55

EP - 59

JO - Topics in antiviral medicine

JF - Topics in antiviral medicine

SN - 2161-5861

IS - 2

ER -